Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have earned an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $43.00.
Several equities research analysts have recently issued reports on the stock. Wedbush assumed coverage on shares of Rocket Pharmaceuticals in a research note on Monday, December 30th. They set an “outperform” rating and a $32.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. The Goldman Sachs Group decreased their price target on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Chardan Capital decreased their price target on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Finally, Jefferies Financial Group began coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $29.00 price target for the company.
Get Our Latest Analysis on Rocket Pharmaceuticals
Institutional Inflows and Outflows
Rocket Pharmaceuticals Trading Up 3.1 %
NASDAQ:RCKT opened at $8.76 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The firm has a market cap of $934.08 million, a price-to-earnings ratio of -3.19 and a beta of 1.03. Rocket Pharmaceuticals has a 52 week low of $8.06 and a 52 week high of $28.67. The firm has a 50-day moving average price of $10.22 and a two-hundred day moving average price of $13.94.
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.06. On average, equities analysts expect that Rocket Pharmaceuticals will post -2.83 earnings per share for the current fiscal year.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Read More
- Five stocks we like better than Rocket Pharmaceuticals
- 5 discounted opportunities for dividend growth investors
- How to Build the Ultimate Everything ETF Portfolio
- The Role Economic Reports Play in a Successful Investment Strategy
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.